• Policy
• The MOHW has won the original drug price lawsuit
• by Lee, Jeong-Hwan Jan 25, 2022 05:55am

• Policy
• MFDS has completed verification of the efficacy of Retevmo
• by Lee, Tak-Sun Jan 25, 2022 05:55am

• Policy
• Xeloda in breast cancer patients is also reimbursed
• by Lee, Hye-Kyung Jan 24, 2022 05:55am

• Policy
• Improve the reimb system to accommodate high-priced drugs
• by Lee, Hye-Kyung Jan 21, 2022 05:56am

• Policy
• Alvogen targets the Korean market with a Spanish biosimilar
• by Lee, Tak-Sun Jan 21, 2022 05:56am

• Policy
• Pt management is required to provide high priced 1 shot tx
• by Lee, Hye-Kyung Jan 21, 2022 05:56am

• Policy
• Dong-A ST enters Phase III trial for its new OAB treatment
• by Lee, Tak-Sun Jan 20, 2022 05:55am

• Policy
• SK Bioscience has completed recruiting phase 3 participants
• by Kim, Jung-Ju Jan 20, 2022 05:55am

• Policy
• Additional Paxlovid for 10,000 people will be introduced
• by Kang, Shin-Kook Jan 20, 2022 05:54am

• Policy
• Bill for Rotarix·RotaTeq to be covered by NIP
• by Lee, Jeong-Hwan Jan 19, 2022 06:06am